Kornimate/medical-research-clean huggingface dataset:
effectiveness of additional self-care acupressure for women with menstrual pain compared to usual care alone

Conditions: Menstrual Pain

Summary: the aim of the study is to evaluate the effectiveness of additional self-care acupressure in women with menstrual pain compared to usual care alone.

menstrual pain is a common problem in young women and one of the the main reasons of short term absence from school or work. there is some evidence that acupuncture and acupressure might be successful in treating of menstrual pain. compared with acupuncture, acupressure offers the possibility for women with menstrual pain to do self-care treatment at home. however, studies have been small and self-care acupressure had been only investigated in one study from taiwan.

Eligibility criteria:
inclusion criteria: * women with dysmenorrhea as defined as cramping pain during every menstrual cycle * age: 18 to 25 years * up to now no prior history of a gynecological disease that could be a reason for dysmenorrhea * women with menstruation in the last six weeks and a duration of menstruation cycles between 3 and 6 weeks * women with moderate and severe pain defined as a score equal or higher than 6 on the numeric rating scale for the worst pain intensity during the last menstruation. * written and oral informed consent * women must be able to complete the baseline questionnaire in paper form, the electronic questionnaire via app and a electronic diary via app. * presence of a smartphone and agreement to do data entry through the app exclusion criteria: * acupressure, acupuncture, shiatsu- or/and tuina massage at the moment or planned in the next 8 months * known or planned pregnancy in the next 8 months.

Keywords: menstrual pain primary dysmenorrhea self-care acupressure
safety, pk and effectiveness of iv peramivir in elderly and higher risk subjects with uncomplicated influenza

Conditions: Influenza

Summary: this study will evaluate the safety, pharmacokinetics and effectiveness of a single dose of 600 mg iv peramivir in the treatment of elderly subjects with acute uncomplicated influenza infection and in subjects with acute uncomplicated influenza infection at higher risk for influenza complications. all subjects will receive iv peramivir.


Eligibility criteria:
inclusion criteria: * a positive influenza rapid antigen test (rat) and/or a fda-approved pcr test and at least one clinical sign or symptom consistent with acute influenza infection as listed below or * clinical signs and symptoms consistent with acute influenza infection consisting of an oral temperature ≥ 100°f (37.8°c) with at least one respiratory symptom of at least moderate severity (cough or rhinitis) and at least one constitutional symptom of at least moderate severity (myalgia \[aches and pains\], headache, feverishness, or fatigue) * influenza symptom onset \ 48-hours but ≤ 72-hours exclusion criteria: * women who plan to breast-feed for the first 48 hours after study drug administration * subjects requiring hospital admission to treat medical condition(s) which could represent complications of influenza. * recent worsening of any chronic medical condition consistent with complications of influenza * current evidence of a bacterial infection requiring antibiotic treatment

Keywords: acute uncomplicated elderly
study to evaluate the immune response to pneumococcal vaccine in alefacept-treated adults with chronic plaque psoriasis

Conditions: Chronic Plaque Psoriasis

Summary: a vaccine causes the immune system to produce antibodies (immune response) to specific germs to protect the patient. this study evaluates the immune response to the pneumococcal vaccine in adults with alefacept-treated chronic plaque psoriasis.

this is a 1 arm study designed to evaluate the immune response to pneumococcal vaccine in adults with alefacept-treated chronic plaque psoriasis.

Eligibility criteria:
inclusion criteria: * subject has chronic plaque psoriasis * subject has at least 5% body surface area affected with psoriasis exclusion criteria: * skin disorder other than plaque psoriasis in affected area * previously immunized with any pneumococcal vaccine * subject has pustular or erythrodermic psoriasis * subject is immunocompromised * six or more herpes simplex virus outbreaks per year * history or malignancy, chronic serious infection or hepatic disease

Keywords: psoriasis alefacept polyvalent pneumococcal vaccine immunization
ranibizumab treatment for age-related macular degeneretion

Conditions: Visual Disorder Due to Age-related Macula Degeneration

Summary: to establish the correlation between visual acuity improvement and qol measurement after ranibizumab treatment for amd patients.


Eligibility criteria:
inclusion criteria: * active primary or recurrent subfoveal choroidal neovascularization lesion due to amd * subjects of either gender age 50 years or older * visual acuity better than 0.05 decimal( 20/400 snellen) * signed informed consent form exclusion criteria: * prior treatment for neovascular amd in the study eye, for example, pdt or anti-vegf therapy * patients whose lesion site evaluated by fa examination is more than 12da in subject eye * patients with treatment of triamcinolone intravitreal injection within 6 months in subject eye * patients with a history of intraocular surgical operation(including cataract)within 3 months in subject eye * patients with serious allergic history to such as fluorescein, indocyanine green, iodophors * the pregnant or lactating woman
investigating trends in quality of life in patients with idiopathic pulmonary fibrosis (ipf) under treatment with nintedanib

Conditions: Idiopathic Pulmonary Fibrosis

Summary: multi-center, non-interventional, prospective cohort study aiming to enroll 240 idiopathic pulmonary fibrosis patients receiving treatment with nintedanib in a consecutive manner from 10-12 reference centers across greece.


Eligibility criteria:
inclusion criteria: * patients ≥40 years of age. * patients that have signed informed consent form. * treatment naive patients with an initial ipf diagnosis no more than 3 months prior to enrolment according to 2011 american thoracic society (ats)/ european respiratory society (ers)/ japanese respiratory society (jrs)/latin american thoracic association (alat) guidelines who are initiating treatment with nintedanib (as monotherapy for ipf) the latest on the enrollement day or have initiated treatment with nintedanib (as monotherapy for ipf) within the past 7 days prior to enrolment. * patients for whom the decision to prescribe therapy with nintedanib according to the locally approved product's summary of product characteristics (smpc) has already been taken prior to their enrolment in the study and is clearly separated from the physician's decision to include the patient in the current study. * patients that are able to read, understand and complete the study specific questionnaires. exclusion criteria: * treatment with nintedanib for more than 7 days prior to study enrolment. * patients receiving a combination therapy of nintedanib \& pirfenidone for ipf. * patients that meet any of the contraindications to the administration of the study drug nintedanib according to the approved smpc. * prior treatment with pirfenidone or other treatment for ipf. * participation in an interventional study. * patients currently receive treatment with any investigational drug/device/intervention or have received any investigational product within 1 month or 5 half-lives of the investigational agent (whichever is longer) before the initiation of therapy with nintedanib.
post-dural puncture headache: a retrospective study

Conditions: Obstetric Anesthesia Problems; Headache; Epidural; Anesthesia, Headache

Summary: neuraxial techniques are widely used in obstetric practice to provide analgesia and anesthesia. a common complication associated with neuraxial anesthesia is post-dural puncture headache (pdph), resulting from unintentional or unintended puncture of the dura mater during insertion of an epidural needle. incidence of pdph after spinal anesthesia is very low due to the widespread use of non-cutting small diameter spinal needles. incidence of "wet tap" during epidural injection has been reported to be 1.5%, with 52-85% of these patients developing pdph. when an obstetric patient develops pdph, institution of an effective treatment is necessary. although pdph tends to resolve spontaneously over a couple of weeks, it carries the risk of potential complications. pdph interfere with the ability of the mother to take care of her baby, increases the risk of chronic headache and limits early ambulation, thereby increasing the risk of venous thrombosis and pulmonary embolism. as important as treating pdph when it occurs is to prevent it when the dura is accidentally punctured during labor epidural placement. multiple therapeutic strategies have been reported in the medical literature to prevent this outcome. preventive measures range from conservative strategies to invasive procedures. bedrest and hydration have been traditionally recommended to try to prevent pdph when a wet tap occurs; however, no conclusive evidence supports their use. the use of oral and intravenous caffeine is insufficiently supported by clinical evidence. epidural morphine and intravenous cosyntropin have been successfully used to prevent pdph. epidural injection of normal saline reduces the gradient for csf leak. the use of saline has shown variable results in different studies. although the results of some studies show insufficient evidence about its effectiveness, administration of epidural saline is a technique relatively devoid of significant adverse effects. the institutional protocol recommends the combination of a multimodal approach to prevention of pdph after accidental dural puncture, based on strategies reported in the medical literature. the protocol consists of the immediate administration of 60 cc of epidural normal saline, followed by two preventive measures administered after delivery. after delivery, 1 mg of intravenous cosyntropin and 3 mg of epidural morphine before catheter removal are administered. this study tests the hypothesis that the multimodal prophylactic protocol described above decreases the incidence of pdph and the need to perform epidural blood patch, compared to other strategies or no prophylactic management.


Eligibility criteria:
inclusion criteria: * pregnant patients who underwent labor epidural and had accidental dural puncture exclusion criteria: * history of migraines or chronic headaches * history of neurological deficits
quetiapine fumarate (seroquel) compared to placebo in the treatment of adolescent patients with schizophrenia

Conditions: Schizophrenia

Summary: the purpose of this study is to demonstrate efficacy and safety of quetiapine fumarate (seroquel) compared with placebo in the treatment of adolescent patients with schizophrenia.


Eligibility criteria:
inclusion criteria: * patient is able to provide written assent and the parents or legal guardian of the patient is able to provide written informed consent before beginning and study related procedures * patient has a documented clinical diagnosis of schizophrenia * patient's parent or legal guardian will be able to accompany the patient at each scheduled study visit exclusion criteria: * patients (female) must not be pregnant or lactating * patients with a known intolerance or lack of response to previous treatment with quetiapine * patients who have previously participated in this study

Keywords: schizophrenia
observational study to evaluate the biomimics 3d stent system: mimics-3d

Conditions: Peripheral Arterial Disease

Summary: the mimics-3d study will evaluate safety, effectiveness and device performance within a real-world clinical population of patients undergoing femoropopliteal intervention.

the mimics-3d study is a prospective, multicentre, observational study of the biomimics 3d stent system in patients undergoing endovascular intervention to relieve symptomatic peripheral arterial disease of the femoropopliteal artery. the study is designed to enable the collection, analysis and reporting of data from "real-world" use of the biomimics 3d stent system used in accordance with the instructions for use (ifu) associated with the product's ce mark approval. data collection will include that relating to safety, effectiveness and device performance and the period of observation during which data will be collected will extend from the index procedure through 3 years (36 months), according to the standard follow-up practice of the enrolling institution.

Eligibility criteria:
inclusion criteria: * patient is age ≥18 and ≤85 years at date of consent. * patient has provided written informed consent for participation in the study prior to index procedure. * patient has documented symptomatic peripheral arterial disease scheduled for treatment with the biomimics 3d stent in accordance with the approved ce mark indication and instructions for use (ifu) exclusion criteria: * patients whose lesions cannot be crossed with a wire and/or balloon catheter and cannot be dilated sufficiently to allow passage of the delivery system. * patients with a history of intolerance or adverse reaction to antiplatelet and/or anticoagulation therapies, bleeding diathesis, severe hypertension or renal failure. * patients with known hypersensitivity to nickel-titanium. * patient has a comorbidity that in the investigator's opinion would limit life expectancy to less than 12 months. * patient is pregnant or breastfeeding. * patient is unable or is unwilling to comply with site standard of care procedures and follow-up visit schedules for patients undergoing femoropopliteal intervention.

Keywords: pad pvd sfa stent
the women in steady exercise research (wiser) survivor trial

Conditions: Lymphedema

Summary: wiser survivor is a one year weight loss and exercise study for sedentary breast cancer survivors who are overweight or obese with breast cancer related lymphedema. there will be four groups in this trial: exercise only, weight loss only, exercise and weight-loss combined, and a control group. the primary purpose of this study is to test the effects of these interventions on clinical lymphedema outcomes. secondary outcomes include weight loss, breast cancer related biomarkers, and quality of life. to the extent that funding will be available, participants will be followed long term to examine effects on recurrence and mortality.


Eligibility criteria:
inclusion criteria: * breast cancer survivor * overweight or obese (bmi of 25 or greater) * must have breast cancer related lymphedema * at least 6 months post-treatment (e.g. surgery, chemotherapy, or radiotherapy) but there will be no upper limit on time elapsed from diagnosis * the eligible age range will have no lower limit. * currently free of cancer exclusion criteria: * medical conditions or medications that would prohibit participation in an exercise program or would negatively impact our ability to test our primary aims * inability to walk for 6 minutes unaided * extremely obese (body mass index greater or equal to 50 kg/m2) * plans for additional (e.g. curative or reconstructive) surgery during the study period * self-report of weight-lifting within the past year * already engaging in 3 or more times weekly aerobic activity of moderate intensity * planning to move away from the area over the next year * current use of weight loss medication (otc or prescription) * self-report of alcohol or substance abuse within the past 12 months, including at-risk drinking (current consumption of more than 14 alcoholic drinks per week) * weight loss of greater than 10 % in the past 3 months * history of bariatric surgery * women who are pregnant

Keywords: lymphedema strength training intervention weight loss intervention breast cancer recurrence cost effectiveness
tokushima night guard for recurrent aphthous stomatitis

Conditions: Aphthous Stomatitis

Summary: the investigators will investigate whether the night guard can suppress the development of recurrent aphthous stomatitis (ras). the investigators will record the patients' oral condition for 60 days before and after intervention with the night guard made of ethylene-vinyl acetate copolymer (eva). the patients' saliva will be analyzed for measurement of inflammatory cytokines or oxidative stress.

the study involved 20 patients (8 male and 12 female) with ras. these patients suffered from ras at least once a month. the investigators will record their oral condition for 60 days before and after intervention with the night guard made of eva. their saliva will be analyzed for further studies including measurement of inflammatory cytokines or oxidative stress.

Eligibility criteria:
inclusion criteria: * patients suffered from recurrent aphthous stomatitis at least once a month exclusion criteria: * people do not have a experience of recurrent aphthous stomatitis

Keywords: aphthous stomatitis night guard inflammatory cytokine
association between biomarkers and kidney function decline in pulmonary hypertension

Conditions: Pulmonary Hypertension; Chronic Kidney Disease

Summary: the objective of this study is to examine the association between urinary and plasma biomarkers and change in estimated glomerular filtration rate (egfr) among patients with pulmonary hypertension (ph).

ph is a severe, progressive disease associated with right ventricular dysfunction, right-sided heart failure (hf) and death. kidney disease is present in approximately 35% of patients with ph, and its presence is associated with an enhanced risk for adverse outcomes, with the risk increasing incrementally with declining kidney function. poor right ventricular function may increase venous congestion, alter ventricular interdependence, decrease effective cardiac output and activate the renin-angiotensin- aldosterone system, thereby aggravating kidney disease. there is a crucial need to better understand the pathophysiological mechanisms linking the failing right heart and the kidney. to date, diagnostic and prognostic biomarkers of kidney disease in ph are lacking. the objective of this study is to examine the association between urinary and plasma biomarkers and change in egfr among patients with ph.

Eligibility criteria:
inclusion criteria: * inpatients aged ≥18 years * undergoing right heart catheterization (rhc) exclusion criteria: * active tumor disease requiring targeted therapy * inflammatory or autoimmune disease with renal involvement requiring systemic immunosuppressive treatment * chronic kidney disease with egfr \<20 ml/min/1.73 m2 * non-kidney failure requiring extracorporeal or peritoneal ultrafiltration for diuretic-resistant volume overload * if they had received non-steroidal anti-inflammatory drugs or intravenous contrast within 72 hours before rhc * prediagnosed glomerulonephritis * polycystic kidney disease * postrenal obstruction * solid organ transplantation * anticipated life expectancy of \<12 months * likelihood of receiving advanced therapy (mechanical circulatory assist device/lung or cardiac transplant) * pregnancy or possibility of pregnancy in the next 12 months * refusal to participate * not available for follow-up visits
comparative effects of alexander techniques and feldenkrais method in parkinson's disease

Conditions: Parkinson Disease

Summary: parkinson's disease (pd) is a neurodegenerative disorder characterized by tremors, rigidity, and postural instability. these symptoms significantly impact balance and increase the risk of falls, which subsequently lead to a heightened fear of falling and a diminished quality of life. alexander technique and the feldenkrais method have shown effects in improving overall well-being. the study is randomized clinical trial will be carried at general hospital. 46 participants meeting the inclusion criteria will be included in this study. participants will be randomly assigned into 2 groups, group a and group b participants will receive alexander techniques and feldenkrais method, respectively. all the groups will receive interventions for three days a week for 8 weeks.

parkinson's disease (pd) is a progressive neurodegenerative disorder characterized by motor symptoms such as tremors, rigidity, bradykinesia, and postural instability. these symptoms significantly impact balance and increase the risk of falls, which subsequently lead to a heightened fear of falling and a diminished quality of life. alexander technique and the feldenkrais method have shown promise in improving motor function and overall well-being. the primary objective of this study is to compare the effects of the alexander technique and the feldenkrais method on balance, fear of falling, and quality of life in patients with parkinson's disease. this randomized clinical trial will be carried at general hospital after the approval of permission letter. total number of 46 participants meeting the inclusion criteria will be included in this study through a non-probability convenient sampling technique. participants will be randomly assigned into 2 groups using computer generated randomization method. group a and group b participants will receive alexander techniques and feldenkrais method, respectively. all the groups will receive interventions for three days a week for 8 weeks. total treatment time will be 40 minutes. the outcome measuring scales used will be berg balance scale and time-up and go to measure balance, fall efficacy scale-international to measure fear of fall, and the parkinson's disease questionnaire (pdq-39) to measure quality of life. the data will be collected at baseline and after 8 weeks of therapy, to measure the outcome measures.

Eligibility criteria:
inclusion criteria: * the age group of 50 to 70 years will be included. * both genders (male and female) * patients diagnosed with parkinson's disease of hoehn and yahr stage (1-3). * patient should be able to stand 10 minutes at least without assistance. * patients should be able to walk with or without assistance. * mmse (score higher than 24). exclusion criteria: * recent surgery or any fracture * visual and hearing impairments. * cvs impairments that interfered with therapy * joint pain or musculoskeletal problem that interfered with therapy

Keywords: alexander techniques balance feldenkrais method fear of fall quality of life parkinson's disease